间皮素作为癌症免疫治疗的生物标志物和治疗靶点
Mesothelin as Biomarker and Therapeutic Target for Immunotherapy in Cancer.
癌症仍是一个关键的全球健康问题，原因在于发现晚、耐药和高死亡率。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
胃癌中 IL36RN 表达增强及其与免疫微环境的关联预测不良预后
英文原题：Enhanced IL36RN Expression and Its Association With Immune Microenvironment Predicts Poor Prognosis in Gastric Cancer.
查看英文原题
Enhanced IL36RN Expression and Its Association With Immune Microenvironment Predicts Poor Prognosis in Gastric Cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
IL36RN 是 GC 中潜在的预后生物标志物和治疗靶点，为精准肿瘤学和免疫治疗干预提供了新途径。
研究思路结论见上方概要
背景
胃癌（GC）仍然是全球范围内一种高发且致命的恶性肿瘤，这凸显了寻找新的治疗靶点并阐明肿瘤微环境（TME）以改善临床结局的迫切需求。
方法
采用癌症基因组图谱（TCGA）数据集分析GC组织中IL36RN mRNA表达。运用生物信息学方法、细胞模型和临床组织微阵列研究IL36RN的功能作用、其在TME中的相互作用及其预后意义。
结果
IL36RN在GC组织中表达显著上调，并与不良生存结局相关。功能实验表明，沉默IL36RN可抑制GC细胞增殖和侵袭。IL36RN表达升高与TME中CD8+ T细胞浸润增强相关，并可作为GC的独立预后指标。
展开英文摘要原文
BACKGROUND
Gastric cancer (GC) remains a prevalent and lethal malignancy worldwide, underscoring the urgent need to identify novel therapeutic targets and elucidate the tumor microenvironment (TME) to enhance clinical outcomes.
METHODS
IL36RN mRNA expression in GC tissues was analyzed using The Cancer Genome Atlas (TCGA) dataset. Bioinformatics approaches, cellular models, and clinical tissue microarrays were employed to investigate the functional role of IL36RN, its interactions within the TME, and its prognostic significance.
RESULTS
IL36RN expression was markedly upregulated in GC tissues and associated with unfavorable survival outcomes. Functional assays demonstrated that IL36RN silencing suppressed GC cell proliferation and invasion. Elevated IL36RN expression correlated with enhanced CD8 + T cell infiltration in the TME and served as an independent prognostic indicator in GC.
CONCLUSIONS
IL36RN represents a potential prognostic biomarker and therapeutic target in GC, offering novel avenues for precision oncology and immunotherapeutic intervention.
论文信息
- 作者
- Zhang X、Jiang S、Yin H、Zhang H、Yang L、Sun P、Kuai X、Chen C
- 单位
- Clinical and Translational Research Center, Affiliated Hospital of Nantong University and Medical School of Nantong University, Nantong, Jiangsu, China.China
- 期刊
- Cancer medicine2025 May
- 原文标识
- PubMed 40347070 · DOI 10.1002/cam4.70954
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →